BIOMEA FUSION (BMEA)
(Delayed Data from NSDQ)
$2.08 USD
+0.12 (6.12%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $2.08 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMEA 2.08 +0.12(6.12%)
Will BMEA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMEA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMEA
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
BMEA: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
Other News for BMEA
BMEA forms Bearish Engulfing on September 17
Is BMEA primed for upward momentum? Pocket Pivot shows up after advancing 3.06%
Biomea Fusion: Promising Clinical Pipeline and Strategic Focus Drive Buy Rating
BMEA forms 20 Day Moving Average Support on September 15
Biomea Fusion (BMEA) Unveils Promising Diabetes Therapy Data